-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Bristol-Myers Squibb (BMS) announced the positive results of two phase 3 clinical trials of its potential "first-in-class" oral selective TYK2 inhibitor deucravacitinib in the treatment of patients with moderate to severe psoriasis.
Psoriasis, also known as psoriasis, is a widespread chronic systemic immune-mediated disease that affects at least 100 million people worldwide.
TYK2 is a member of the JAK family and is an intracellular signal kinase that mediates the signal transduction of IL-23, IL-12 and type I interferon (IFN).
▲Deucravacitinib has a unique mechanism of action (picture source: Bristol-Myers Squibb official website)
Deucravacitinib developed by BMS is an oral selective TYK2 inhibitor.
In two randomized, double-blind, placebo and oral active-controlled Phase 3 clinical trials, a total of more than 1,600 patients with moderate to severe psoriasis received deucravacitinib, PDE4 inhibitor apremilast, or placebo.
Using PASI 75 (meaning a 75% improvement in the patient’s psoriasis area and severity index) as a measure, after 16 weeks of treatment, the proportion of patients treated with deucravacitinib that reached PASI 75 was 58.
▲Deucravacitinib significantly improved the proportion of patients reaching PASI 75 in two phase 3 clinical trials (picture source: reference [2])
Using sPGA 0/1 (meaning that the patient’s skin symptoms are completely or almost completely cleared according to the doctor’s overall assessment) as a measure, after 16 weeks of treatment, the proportion of patients with deucravacitinib reaching this standard was 53.
▲Deucravacitinib significantly improved the proportion of patients reaching sPGA 0/1 in two phase 3 clinical trials (picture source: reference [2])
In terms of safety, deucravacitinib also has a good performance.
▲Bristol-Myers Squibb will promote the clinical project of deucravacitinib in the treatment of various immune-mediated diseases (picture source: reference [2])
"The findings of these two studies prove that deucravacitinib may become the preferred oral therapy for patients with psoriasis.
Reference materials:
[1] Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast).
[2] AAD 2021 Investor Presentation.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.